Independent Conference Coverage of the IASLC 2022 World Conference on Lung Cancer
  • CME

August 6-9, 2022; Vienna, Austria
Review expert perspectives on the most clinically relevant data on lung cancers presented at the 2022 IASLC World Conference on Lung Cancer.
Wade T. Iams, MD, MSCI
Heather Wakelee, MD, FASCO
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 25, 2022 Expiration: October 24, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice, considering expert guidance, to optimize the care of patients with lung cancer
  • Identify subpopulations of patients with lung cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate new data on novel agents and therapeutic approaches for patients with lung cancer

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.
Turning Point Therapeutics, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Wade T. Iams, MD, MSCI

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Wade T. Iams, MD, MSCI: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, EMD Serono, Janssen, Jazz, Mirati, Takeda.
Heather Wakelee, MD, FASCO

Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Heather Wakelee, MD, FASCO: consultant/advisor/speaker: Mirati; researcher: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, Bristol Myers Squibb, Clovis Oncology, Genentech/Roche, Helsinn, Merck, Novartis, SeaGen, Xcovery.

Staff

Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.
Brian Purves, PharmD, MBA
Brian Purves, PharmD: salary (ended within past 24 mos): AstraZeneca
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with lung cancer.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 25, 2022, through October 24, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Released: January 23, 2023

On-demand webcast from a live satellite symposium at SITC 2022 on current use of IO therapy in lung cancer, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 17, 2023 Expired: January 16, 2024

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings